CoChat

Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy

Open access
Tardif, Jean-Claude, O'Meara, Eileen, Komajda, Michel, Böhm, Michael, Borer, Jeffrey S., Ford, Ian, Tavazzi, Luigi, Swedberg, Karl · 2011 · European Heart Journal

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

AIMS: The SHIFT echocardiographic substudy evaluated the effects of ivabradine on left ventricular (LV) remodelling in heart failure (HF). METHODS AND RESULTS: Eligible patients had chronic HF and systolic dysfunction [LV ejection fraction (LVEF) ≤35%], were in sinus rhythm, and had resting heart rate ≥70 bpm. Patients were randomly allocated to ivabradine or placebo, superimposed on background therapy for HF. Complete echocardiographic data at baseline and 8 months were available for 411 patients (ivabradine 208, placebo 203). Treatment with ivabradine reduced LVESVI (primary substudy endpoint) vs. placebo [-7.0 ± 16.3 vs. -0.9 ± 17.1 mL/m(2); difference (SE), -5.8 (1.6), 95% CI -8.8 to -2.7, P< 0.001]. The reduction in LVESVI was independent of beta-blocker use, HF aetiology, and baseline LVEF. Ivabradine also improved LV end-diastolic volume index (-7.9 ± 18.9 vs. -1.8 ± 19.0 mL/m(2), P= 0.002) and LVEF (+2.4 ± 7.7 vs. -0.1 ± 8.0%, P< 0.001). The incidence of the SHIFT primary composite outcome (cardiovascular mortality or hospitalization for worsening HF) was higher in patients with LVESVI above the median (59 mL/m2) at baseline (HR 1.62, 95% CI 1.03-2.56, P= 0.04). Patients with the largest relative reductions in LVESVI had the lowest event rates. CONCLUSION: Ivabradine reverses cardiac remodelling in patients with HF and LV systolic dysfunction.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehr311

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Trial profile. FAS, full analysis set.
Figure 1 Trial profile. FAS, full analysis set.CC BY-NC · PubMed Central
Figure 2 (A) Relative change in left ventricular end-systolic volume index (LVESVI) and (B) absolute change in left ventricular ejection fraction (LVEF) from baseline to 8 months. The grey and white bars represent percentages of patients reaching echocardiographic criteria for the ivabradine and placebo groups, respectively.
Figure 2 (A) Relative change in left ventricular end-systolic volume index (LVESVI) and (B) absolute change in left ventricular ejection fraction (LVEF) from baseline to 8 months. The grey and white bars represent percentages of patients reaching echocardiographic criteria for the ivabradine and placebo groups, respectively.CC BY-NC · PubMed Central
Figure 3 Kaplan–Meier cumulative event curves for the SHIFT primary composite endpoint of cardiovascular death or hospitalization for worsening heart failure in the placebo group split by median left ventricular end-systolic volume index (LVESVI) ≥59 vs. <59 mL/m2.
Figure 3 Kaplan–Meier cumulative event curves for the SHIFT primary composite endpoint of cardiovascular death or hospitalization for worsening heart failure in the placebo group split by median left ventricular end-systolic volume index (LVESVI) ≥59 vs. <59 mL/m2.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Research works printed but not linked: 1

  1. 2007, Protection of endothelial function by long-term heart rate reduction induced by ivabradine in a rat model of chronic heart failure, Eur Heart J, 28, 48

Cited by

See all 304

Metadata

Authors
Tardif, J.-C., O'Meara, E., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Tavazzi, L., & Swedberg, K.
Affiliations
  • Montreal Heart Institute (CA)
  • Universitätsklinikum des Saarlandes (DE)
  • SUNY Downstate Health Sciences University (US)
  • University of Glasgow (GB)
  • Maria Cecilia Hospital (IT)
  • University of Gothenburg (SE)
Corresponding author
Tardif, Jean-Claude
Venue
European Heart Journal
Published
2011-08-29
Volume
32
Issue
20
Pages
2507-2515
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2170675714
Cited by
300
References
23
Citations by year
2026: 4 · 2025: 8 · 2024: 13 · 2023: 11 · 2022: 17 · 2021: 20 · 2020: 20 · 2019: 14 · 2018: 24 · 2017: 20 · 2016: 28 · 2015: 30 · 2014: 20 · 2013: 32 · 2012: 31
FWCI
19.80
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • European Heart Journal (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords
ivabradine, heart rate reduction, left ventricular remodeling, heart failure with reduced ejection fraction, systolic dysfunction, left ventricular end-systolic volume index, left ventricular end-diastolic volume index, left ventricular ejection fraction, SHIFT trial, cardiovascular mortality, hospitalization for worsening heart failure, beta-blockers
MeSH terms
Ivabradine, Aged, Anti-Arrhythmia Agents, Arrhythmias, Cardiac, Benzazepines, Double-Blind Method, Echocardiography, Female, Heart Failure, Humans, Male, Middle Aged, Stroke Volume, Ventricular Dysfunction, Left, Ventricular Remodeling

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. https://app.cochat.ai/papers/10.1093/eurheartj/ehr311
The paper
Tardif, J.-C., O'Meara, E., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Tavazzi, L., & Swedberg, K. (2011). Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal. https://doi.org/10.1093/eurheartj/ehr311

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.